Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Stopped Sponsor decision.

Conditions

• Chronic Graft Versus Host Disease

Interventions

• DRUG: Belumosudil

Sponsor

Kadmon, a Sanofi Company